Organic arsenicals were the first antimicrobial agents specifically synthesized for the treatment of infectious diseases such as syphilis and sleeping sickness. For the treatment of diseases caused by trypanosomatid parasites, organic derivatives of arsenic and the related metalloid antimony are still the drugs of choice. Arsenic trioxide, As203, has been used for a long time in traditional Chinese medicines for treatment of various diseases, and it has recently been shown to be clinically active in acute promyelocytic leukemias. Resistance to metalloid salts is found in bacteria, fungi, parasites and animals. In some organisms, resistance involves overproduction of intracellular thiols. In many cases, resistance to arsenic salts is the result of removal of the metalloid from the cytosol usually by extrusion from the cell. In eukaryotes resistance to arsenic and antimony is conferred by membrane transport proteins of the MRP family. The human MRP1, a member of this family, is frequently amplified in cancer cells and it is well-documented that MRPl-overexpressing cells poorly accumulate arsenic and antimony because of enhanced cellular effiux which depends on the presence of GSH.
INTRODUCTION
The introduction of antibiotics in the 1940s opened up a completely new prospect to medical science and the treatment of infectious diseases. A broad variety of drugs active against several infectious organisms were discovered or developed. However, the widespread, and sometimes uncontrolled, use of these drugs has led to the emergence of defense mechanisms that, at present, are the major drawback to the drug-based treatment of infectious diseases and cancers. Most strikingly, such resistance is not restricted to the drugs (or analogs) used in the treatment but also involves several structurally and functionally unrelated compounds. This phenomenon, which has been tenaaed multidrug resistance (MDR) can be caused by various mechanisms and is known to play an important role in the drug resistance of a broad range of pathogenic bacteria, parasitic protozoa, and tumor cells. Altogether, these diseases are responsible for millions of deaths yearly/1-4/.
Multidrug resistance (MDR) in tumour cells is often caused by the overexpression of two transporters the P-glycoprotein (P-gp) and the multidrug resistance associated protein (MRP1). Both proteins belong to the superfamily of the so-called ATP binding cassette transport proteins (ABC transporters), which are known to be dependent on ATP hydrolysis for the translocation of substrate across membranes/5, 6/.
P-gp is an unusual ABC protein in that it appears to be highly promiscuous: hundreds of compounds have been identified as substrates. The spectrum of MDR compounds includes a large number of anticancer drugs (e.g., anthracyclines, vinca alkaloids, taxanes) as well as steroids, fluorescent dyes, rhodamine, and the emitting radiopharmaceutical 99m'rc-MIBi /1,2/. P-gp can transport neutral and positively charged molecules but not negatively charged ones.
MRP1 belongs to a second class of transporters whose mechanism of action differs from that of P-gpclass transporters. MRP1 can transport a large range of drugs conjugated to negatively charged hydrophilic ligands such as glutathione, glucuronic acid, and sulfate/7-9/. It can also transport arsenite and antirnonite when GSH is present. MRP is also able to confer resistance to drugs that are not known to be conjugated to any acidic ligand, such as doxorubicin or the vinca alkaloids. Such resistance seems to require the presence of glutathione, and available evidence indicates that MRP1 can co-transport drug with glutathione and even glutathione alone can be transported, though at a lower rate/7, 10-12/. MRPI can also transport neutral, as well as positively negatively charged, molecules.
In summary, a clear distinction in the mechanism of translocation of substrates by MRP1 or P-gp is indicated by the finding that, in most cases, the MRPl-mediated transport.of substrates is inhibited by depletion of intracellular glutathione (GSH), which has no effect on their P-gp-mediated transport. In this small review we will focus on the resistance to arsenic-and antimony-based drugs.
ARSENIC: TOXICITY AND METABOLISATION
Arsenic is synonymous with poison and geological sources of inorganic arsenic are environmental problems worldwide. This metalloid is ubiquitously present in the environment, where it occurs mainly as compounds of As(Ill) and As(V) ions. Its toxicity makes it a useful ingredient in herbicides and pesticides Epidemiological studies have shown that chronic exposure to inorganic arsenic" arsenite, As(III)O33, and arsenate, As(V)O43-, result in liver injury, peripheral neuropathy, and an increased incidence of cancer of the lung, skin, bladder, and liver/13-16/. In addition, occupational exposure to arsenic increases the lung cancer incidence among smokers and underground miners in a manner consistent with a synergistic interaction of arsenic with tobacco smoke or radon found in mines.
Arsenite 2" nt-CH3+---> (CH3)2 As(V) O2-(CH3)2As(V) 02" + 2e + 2H+--> (CH3)2 As(Ill) O+ H20
Here, the reduction of arsenic fi'om pentavalency to trivalency is a prerequisite for its oxidative methylation, suggesting both trivalent and pentavalent metabolites to be intermediates or final products in this metabolic pathway. Methylated arsenicals have unique biological effects. At high dose levels they are tumor promoters and carcinogen. Most data suggest that the pathway for the methylation of arsenic, which produces methylated arsenicals containing As(V), should be regarded as a mechanism for the activation, not for the detoxification, of arsenic. Therefore, methyl As and dimethyl As are likely to be the metabolites of arsenic that account for at least some of the adverse effects associated with chronic exposure to arsenic/21-23/.
A central issue in arsenic biochemistry is the role of sulfhydryl-containing molecules and especially of gluthathione (GSH) because the reduction of As(V) may use glutathione as a source of reducing equivalents /24, 25/; it can also be catalyzed by As(V) reductases /26, 27/. GSH is a tripeptide, (,-L-Glutamyl-LCysteinylglycine) and a potentially polydentate ligand present in many cells at millimolar concentration. Generally it is the most abundant nonprotein thiol. GSH is known to bind a variety of essential and nonessential metals, playing critical roles in the cellular and systemic metabolism of these metals /28/. The formation of the As(III)-GSH complexes have been thoroughly studied/24, 25/. It has been shown that As(GS)3 is formed and that the binding site is the cysteinyl sulfydryl. However, it must be pointed out that these experiments have been performed at acidic pH value (-3) and that about six hours are required for the complete formation of the complex/25, 29/. The kinetics of formation of As(GS)3 is therefore very slow at pH 3 and even slower at pH 7.3 . According to the data of Delnomdedieu et al./25/, the As(GS)3 complex, which has been prepared at acidic pH value, is stable over the pH range from 1.5 to 7.0 7.5 and rather unstable above pH 7.5. Thus, there is little chance to observe its major formation when As(Ill) and GSH are mixed at pH higher than 7.
Actually, with one exception /30/, the formation of arsenic-glutathione complex has not been demonstrated in vivo. Thus only Kala et As seen earlier, bacteria and yeast that live in environments contaminated with arsenate reduce the element intracellularly to arsenite as part of the mechanism that was evolved to evade the toxic effects of this heavy metal/35/. Given that Leishmania spp. are not necessarily exposed to heavy metals in their natural habitats (sandflies and vertebrates), they may not have developed this type of protective mechanism. In fact, by reducing nontoxic Sb(V), Leishmania actually expose themselves to the lethal effects of Sb (III).
Actually, many patients fail to respond to the treatment of drugs containing antimony, because prasites resistant to these drugs are now becoming widespread /40, 41/. Leishmania strains resistant not only to pentavalent antimony but also to trivalent antimony and arsenite have been described/42/.
One mechanism of resistance recently described is the inability of the parasite to reduce Sb(V) to Sb(III) /43/. Stage-specific intracellular Sb(V) reducing activity was apparent in amastigotes which reduced the negligibly toxic Sb(V) to highly toxic Sb(III). This amastigote-specific reducing activity was deficient in the pentostam-resistant mutant L. Donovani Ldl S.20. These data indicate that Sb(V) anti-leishmanial activity is dependent on its reduction to Sb(III). The mechanism of this novel intracellular Sb(V) reduction has yet to be identified, and it may or may not be enzymatic. h, the extra-and intracellular concentrations of arsenic are the same, indicates that there is a transmembrane equilibrium of the species that diffuses passively through the membrane; this means that As(OH). is still present inside the cells, without undergoing a chemical transformation and is passively effiuxed from the cells. These data are corroborated by the observations that i) at pH -7.3, the rate of complexation of GSH to arsenic is very slow; ii) the rate of passive uptake and efflux of arsenic species in sensitive cells does not depend on GSH level (if arsenic-GSH complex was formed one could have expected different rates of arsenic accumulation inside the GSH-depleted or GSH-rich sensitive cells). So we concluded that within the first 1-2 hours the amount of arsenic-glutathione complex, if any, is very low. Now as time elapses, one observes a slow increase of the arsenic intracellular concentration which becomes higher than the extracellular arsenic concentration. One very likely interpretation is that the arsenic accumulation is due to the transformation of the permeant As(OH)3 species into another one which is unable to diffuse freely through the membrane such as an As-glutathione complex or arsenic binding to thiol-containing proteins. All this reasoning helds for antimony.
Amplification of the P-gp
The important point is that a negligible amount, if any, of As-GSH complex is formed during the first 1-2 hours. The arsenic concentration is lower in resistant cells than in sensitive cells, thus, the arsenic species is pumped out by MRP 1. This shows that As(OH)3 species is the substrate for MRP 1. In addition to the observation that there is no active efflux in GSH-depleted cells, we suggest that As(OH)3 could be co-transported with GSH. In addition, 2 IaM MK571 are able to inhibit the 50% of MRPl- 
